RxDoctor Payments DataLook up a doctor →

Bernard Robinowitz, MD

Dermatology · Tulsa, OKNPI 1598760712

Payments from drug & device makers

$13,861in general payments, 2019–2025

Across 736 payments — averaging $18.83 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$3K
  • Johnson & Johnson$2K
  • E.r. Squibb & Sons, L.L.C.$1K
  • Novartis$1K
  • Lilly USA, LLC$1K
  • Pfizer$1K
  • plus $5K from 22 others

What the payments were for

  • Food & beverage$13,42297%
  • Education$4393%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$13,861 in reported general payments places this provider in the 80th percentile of 114 dermatology providers in Oklahoma.

See all dermatology providers in Oklahoma

Medicare billing

Part B allowed, 2024
$259,787
Medicare patients
1,087
Services billed
3,253

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OtezlaApremilast77$377,413
SotyktuDeucravacitinib26$187,207
Dupixent PenDupilumab37$139,885
Cosentyx Sensoready (2 Pens)Secukinumab13$94,390
RinvoqUpadacitinib12$75,631
Dupixent SyringeDupilumab13$47,759
Acitretin82$28,638
ZoryveRoflumilast14$12,261
Tacrolimus30$6,685
Pimecrolimus13$4,549
Triamcinolone Acetonide175$3,009
Fluocinonide56$2,878
Fluorouracil41$2,563
Fluconazole215$2,180
Minocycline Hcl83$1,994

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AmgenOtezla$814$377,41377 claims
E.r. Squibb & Sons, L.L.C.Sotyktu$1,305$187,20726 claims
AbbVieRinvoq$2,774$75,63112 claims
Arcutis Biotherapeutics, Inc.Zoryve$582$12,26114 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 114 dermatology providers in Oklahoma.

Other dermatology in Tulsa

See the full list for Oklahoma

Where these figures come from

Is this you, or does something look wrong? →